Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T L Williams

Showing results (91-100 of 93) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 93 results.
Neuroscience|April 1, 1996
Distribution of alpha 1A, alpha 1B and alpha 1E voltage-dependent calcium channel subunits in the human hippocampus and parahippocampal gyrusN C Day, P J Shaw, A L McCormack, et al.
Journal of the Neurological Sciences|January 1, 2021
Measuring coping in people with amyotrophic lateral sclerosis using the Coping Index-ALS: A patient derived, Rasch compliant scaleC A Young, C J McDermott, T L Williams, et al.
The Lancet. Neurology|March 5, 2013
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial, K E Morrison, S Dhariwal, et al.
Pageof 10

Showing results (91-100 of 93) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 93 results.
Neuroscience|April 1, 1996
Distribution of alpha 1A, alpha 1B and alpha 1E voltage-dependent calcium channel subunits in the human hippocampus and parahippocampal gyrusN C Day, P J Shaw, A L McCormack, et al.
Journal of the Neurological Sciences|January 1, 2021
Measuring coping in people with amyotrophic lateral sclerosis using the Coping Index-ALS: A patient derived, Rasch compliant scaleC A Young, C J McDermott, T L Williams, et al.
The Lancet. Neurology|March 5, 2013
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial, K E Morrison, S Dhariwal, et al.
Pageof 10